Seth et al. [15] used an adenovirally modified epigastric flap to produce a virally delivered prodrug (VDEPT) consisting of herpes simplex virus-thymidine kinase (HSV-TK)/ganciclovir (GCV) to treat a rat model of residual disease using glioma cells. This evidence concerns the gene TKT and central nervous system cancer.